BTR Capital Management’s Novartis NVS Stock Holding History

BTR Capital Management’s Portfolio NVS Stock Details NVS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q2	–	Sell	-2,885	Closed	-$238K	–	158
2020 Q1	$238K	Buy	+2,885	New	+$257K	0.05%	130
2018 Q4	–	Sell	-2,885	Closed	-$223K	–	171
2018 Q3	$223K	Buy	+2,885	New	+$213K	0.04%	158
2017 Q1	–	Sell	-3,405	Closed	-$241K	–	163
2016 Q4	$241K	Hold	3,405	–	–	0.05%	145
2016 Q3	$241K	Buy	3,405 +57	+2%	+$4.15K	0.05%	145
2016 Q2	$248K	Sell	3,348 -21,836	-87%	-$1.51M	0.06%	139
2016 Q1	$1.64M	Sell	25,184 -10,233	-29%	-$696K	0.38%	59
2015 Q4	$2.73M	Sell	35,417 -224	-0.6%	-$17.8K	0.62%	46
2015 Q3	$2.94M	Buy	35,641 +6,083	+21%	+$541K	0.7%	48
2015 Q2	$2.6M	Buy	29,558 +4,593	+18%	+$421K	0.61%	51
2015 Q1	$2.21M	Buy	+24,965	New	+$2.21M	0.53%	56

Other funds holding NVS

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

Loomis, Sayles & Company Boston, Massachusetts $74.3B AUM 24.01% 1-Year Est. Return

Fisher Asset Management Camas, Washington $295B AUM 31.6% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Mawer Investment Management Calgary, Alberta, Canada $15.4B AUM 10.9% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Boston Partners Boston, Massachusetts $95.5B AUM 28.4% 1-Year Est. Return

BTR Capital Management's NVS Position: Q2 2020 in Review

BTR Capital Management sold out of Novartis (NVS) in Q2 2020, closing a stake of 2,885 shares — an estimated $238K sold.

BTR Capital Management first reported a position in NVS in Q1 2015 and held it in 10 quarters. The position peaked at $2.94M in Q3 2015. 1,128 funds tracked by Wall St. Rank hold NVS as of Q2 2020.

BTR Capital Management reported no remaining Novartis position as of Q2 2020 after selling out during the quarter.
BTR Capital Management sold 2,885 Novartis shares in Q2 2020, an estimated $238K.
BTR Capital Management first reported a position in Novartis in Q1 2015 and held it in 10 quarters.
BTR Capital Management's Novartis position peaked at $2.94M in Q3 2015.
1,128 funds tracked by Wall St. Rank held Novartis as of Q2 2020.

Based on BTR Capital Management's 13F filing for Q2 2020, filed 23 Jul 2020.